Efficacy of isosorbide mononitrate combined with perindopril tert-butylamine in the treatment of elderly patients with chronic heart failure

doi:10.3760/cma.j.issn.1007-1245.2023.09.021

Abstract

Abstract:

Objective　To analyze the short-term efficacy of isosorbide mononitrate combined with perindopril tert-butylamine in the treatment of elderly patients with chronic heart failure and its effects on serum levels of growth differentiation factor-15 (GDF-15) and soluble growth stimulation-expressed gene 2 protein (sST2). Methods　It was a randomized controlled trial. A total of 120 elderly patients with chronic heart failure admitted to The Third People's Hospital of Liaocheng from February 2019 to January 2021 were divided into two groups by the random number table method, with 60 cases in each group. In the control group, there were 35 males and 25 females, aged (70.96±3.85) years. In the observation group, there were 38 males and 22 females, aged (71.55±4.03) years. After admission, both groups were given routine treatment. The control group received oral perindopril tert-butylamine treatment before meals in the morning, and the observation group was additionally given oral isosorbide mononitrate treatment on this basis. Both groups received continuous treatment for 1 month. The clinical efficacies, cardiac function and serum markers of heart failure [N-terminal precursor brain natriuretic peptide (NT-proBNP), blood insulin growth faction-1 (IGF-1), troponin T (cTnT), GDF-15, and sST2] before and after treatment, and adverse reactions during treatment were compared between the two groups. χ² test and t test were used. Results　The total effective rate of the observation group was 85.00% (51/60), and that of the control group was 70.00% (42/60), with a statistically significant difference between the two groups (χ²=3.871, P=0.049). After treatment, the left ventricular end-systolic diameter (LVESD) [(42.55±5.31) mm], left ventricular end-diastolic diameter (LVEDD) [(46.78±8.10) mm], NT-proBNP [(274.20±102.11) ng/L], cTnT [(76.21±9.28) ng/L], GDF-15 [(554.87±23.54) ng/L], sST2 [(8.28±2.47) μg/L] in the observation group were lower than those in the control group [(51.69±4.27) mm, (54.63±8.14) mm, (824.33±412.74) ng/L, (85.77±10.58) ng/L, ( 845.98±20.14) ng/L, and (45.14±6.22) μg/L], and the left ventricular ejection fraction (LVEF) [(59.78±5.01) %], cardiac output (CO) [(5.57±0.68) L/min], stroke output (SV) [(70.81±6.51) ml], and IGF-1 [(119.87±20.98) μg/L] were all higher than those in the control group [(47.63±6.15) %, (5.09±0.64) L/min, (65.76±6.83) ml, and (110.47±23.58) μg/L], with statistically significant differences (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (χ²=0.120, P=0.729). Conclusion　Isosorbide mononitrate combined with perindopril tert-butylamine in the treatment of elderly patients with chronic heart failure can better improve their clinical symptoms and signs, promote the improvement of cardiac function, and regulate their serum biomarker levels, which is responsive and safe.

Key words:

Chronic heart failure, Isosorbide mononitrate, Perindopril tert-butylamine, Cardiac function, Short-term efficacy

摘要：

目的　分析老年慢性心力衰竭患者行单硝酸异山梨酯联合培哚普利叔丁胺治疗的近期疗效及对血清生长分化因子-15（GDF-15）、可溶性生长刺激表达基因2蛋白（sST2）水平的影响。方法　本研究为随机对照试验，选取2019年2月至2021年1月聊城市第三人民医院收治的老年慢性心力衰竭患者120例为研究对象，采用随机数字表法分为两组，各60例。对照组男35例、女25例，年龄（70.96±3.85）岁；观察组男38例、女22例，年龄（71.55±4.03）岁。两组入院后均给予常规治疗，对照组患者晨起饭前口服培哚普利叔丁胺治疗，观察组在其基础上加用口服单硝酸异山梨酯治疗，两组均连续治疗1个月。对比两组临床疗效、治疗前后心功能、血清心力衰竭标志物水平［N末端脑钠肽前体（NT-proBNP）、血液胰岛素生长因子-1（IGF-1）、肌钙蛋白T（cTnT）、GDF-15、sST2］及治疗期间不良反应。采用χ²检验、t检验。结果　观察组临床总有效率为85.00%（51/60），高于对照组70.00%（42/60），差异有统计学意义（χ²=3.871，P=0.049）。治疗后，观察组左心室收缩末期内径（LVESD）［（42.55±5.31）mm］、左心室舒张末期内径（LVEDD）［（46.78±8.10）mm］、NT-proBNP ［（274.20±102.11）ng/L］、cTnT ［（76.21±9.28）ng/L］、GDF-15 ［（554.87±23.54）ng/L］、sST2指标［（8.28±2.47）μg/L］均低于对照组［（51.69±4.27）mm、（54.63±8.14）mm、（824.33±412.74）ng/L、（85.77±10.58）ng/L、（845.98±20.14）ng/L、（45.14±6.22）μg/L］，左心室射血分数（LVEF）［（59.78±5.01）%］、每分心输出量（CO）［（5.57±0.68）L/min］、每搏心输出量（SV）［（70.81±6.51）ml］、IGF-1指标［（119.87±20.98）μg/L］均高于对照组［（47.63±6.15）%、（5.09±0.64）L/min、（65.76±6.83）ml、（110.47±23.58）μg/L］，差异均有统计学意义（均P<0.05）。两组治疗期间不良反应发生率比较，差异无统计学意义（χ²=0.120，P=0.729）。结论　单硝酸异山梨酯联合培哚普利叔丁胺治疗老年慢性心力衰竭可改善患者临床症状、体征及心功能，调节患者血清生物标志物水平，安全性有保障。

关键词:

慢性心力衰竭, 单硝酸异山梨酯, 培哚普利叔丁胺, 心功能, 近期疗效

Dou Dongfeng, Liu Hongguang, Zhang Lifen.

Efficacy of isosorbide mononitrate combined with perindopril tert-butylamine in the treatment of elderly patients with chronic heart failure [J]. International Medicine and Health Guidance News, 2023, 29(9): 1276-1280.

窦东锋刘洪光张丽芬.

单硝酸异山梨酯联合培哚普利叔丁胺治疗老年慢性心力衰竭患者的疗效 [J]. 国际医药卫生导报, 2023, 29(9): 1276-1280.

References

[1] 周全. 贝那普利联合美托洛尔对老年高血压合并心力衰竭的血压控制及Gal-3及MAU水平的影响[J]. 湖南师范大学学报(医学版),2019,16(6):64-67.
[2] 邱英茹. 心肌代谢重构在慢性心力衰竭进展中的作用[J]. 心血管病学进展,2018,39(2):205-209.DOI:10.16806/j.cnki.issn.1004-3934.2018.02.019.
[3] 国家卫生计生委合理用药专家委员会,中国药师协会. 冠心病合理用药指南[J/CD]. 中国医学前沿杂志(电子版),2016,8(6):19-108.DOI:10.3969/j.issn.1674-7372.2016.06.007.
[4] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志,2018,46(10):760-789.DOI:10.3760/cma.j.issn.0253- 3758.2018.10.004.
[5] 葛均波, 徐永健.内科学[M].第8版.北京:人民卫生出版社,2013:89-92.
[6] Wada K, Bunya N, Kakizaki R, et al. Successful use of veno-arterial extracorporeal membrane oxygenation for septic cardiomyopathy in a patient with pre-existing chronic heart failure[J].Acute Med Surg,2019,6(3):301-304.DOI:10.1002/ams2.407.
[7] 魏刚,房万菊,周湘忠,等. 螺内酯联合美托洛尔对老年慢性心力衰竭病人左室重构及心功能的影响[J]. 中西医结合心脑血管病杂志,2018,16(4):451-455.DOI:10.3969/j.issn.1672-1349.2018.04.019.
[8] 罗高蓉,葛尤. 用不同剂量的培哚普利叔丁胺对心肌梗死并发心力衰竭患者进行治疗的效果对比[J]. 当代医药论丛,2020,18(1):110-111.
[9] 吕莹晖. 左西孟旦与环磷腺苷葡胺治疗顽固性心衰的临床疗效[J]. 湖北科技学院学报(医学版),2021,35(1):44-46.DOI:10.16751/j.cnki.2095-4646.2021.01.0044.
[10] 李敏,李虎,王逵,等. 硝普钠联合硝酸甘油治疗急性心力衰竭的疗效及对血浆AngⅡ,NO,ET-1,Cys-C的影响[J]. 中西医结合心脑血管病杂志,2018,16(3):330-333.DOI:10.3969/j.issn.1672-1349.2018.03.021.
[11] 李崇耀,张曼,赵鸿斌,等. 沙库巴曲缬沙坦联合芪苈强心胶囊治疗慢性心力衰竭患者的临床疗效观察[J]. 疑难病杂志,2020,19(7):667-671.DOI:10.3969/j.issn.1671-6450. 2020.07.006.
[12] 戴红梅,朱义芳. 慢性心力衰竭患者血清TNF-α、BNP、Cys-C水平与心肾功能的关系[J]. 中国医药导报,2019,16(16):155-158,162.
[13] 陈亚君,乔雯雯,薛鸿群.胺碘酮联合环磷腺苷葡胺及琥珀酸美托洛尔治疗急性左心衰伴房颤的疗效及对患者心功能和近期心血管事件的影响分析[J].四川解剖学杂志,2020,28(1):24-25.DOI:10.3969/j.issn.1005-1457.2020. 01.011.
[14] 李雨晴,张孟材,叶张章,等. 人参强心汤联合美托洛尔治疗慢性心力衰竭的效果分析及对血清指标和心功能的影响[J]. 湖南师范大学学报(医学版),2021,18(3):226-229.DOI:10.3969/j.issn.1673-016X.2021.03.065.
[15] 陈丽华,程东. 心痹汤联合西药治疗冠心病慢性心力衰竭气虚血瘀证临床研究[J]. 新中医,2020,52(8):63-66.DOI:10.13457/j.cnki.jncm.2020.08.019.
[16] 杜随杨. 单硝酸异山梨酯缓释片联合多巴胺、呋塞米治疗慢性肺源性心脏病心力衰竭的疗效观察[J]. 实用临床医药杂志,2018,22(11):117-119.DOI:10.7619/jcmp. 201811034.
[17] 谢诚,叶静,缪丽燕. 61例心力衰竭患者血管紧张素受体脑啡肽酶抑制剂沙库巴曲缬沙坦的应用分析[J]. 中国药房,2019,30(8):1124-1127.DOI:10.6039/j.issn.1001-0408. 2019.08.21.
[18] 王婷,王正雨,薛乐刚,等. 环磷腺苷葡胺联合单硝酸异山梨酯治疗慢性心力衰竭患者的效果分析[J]. 实用临床医药杂志,2022,26(10):73-76.DOI:10.7619/jcmp.20215189.
[19] 普顺华,关英霞,杨志刚,等. 沙库巴曲缬沙坦治疗左心室射血分数降低心力衰竭患者的临床疗效观察[J]. 中国心血管病研究,2019,17(3):266-269.DOI:10.3969/j.issn.1672- 5301.2019.03.016.
[20] 姬东坡,李秋珍,张曼. 盐酸维拉帕米联合去乙酰毛花苷注射液对冠心病快速房颤伴急性心力衰竭患者心室率及心肌供血状态的影响[J]. 国际医药卫生导报,2020,26(9):1250-1253.DOI:10.3760/cma.j.issn.1007-1245.2020. 09.019.